These findings reinforce the importance of immunophenotypic profiling in DLBCL, highlighting PD-L1, PD-1, and immune cell infiltration as potential prognostic and treatment biomarkers. This evidence concerns the gene PDCD1 and diffuse large B-cell lymphoma.